Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

Investing

Merck : MRK

All Merck Articles

1086 Articles

Paul Ausick | Apr 14, 2016 at 4:01 PM EDT

The 4 Stocks That Buoyed the DJIA on Thursday

April 14, 2016: Markets opened slightly higher Thursday following rather cool data on the consumer price index and fewer new…

Chris Lange | Apr 12, 2016 at 9:50 AM EDT

Short Sellers Become More Selective in Major Pharma

The March 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Paul Ausick | Apr 6, 2016 at 4:01 PM EDT

The 4 Stocks That Dominated the Dow on Wednesday

April 6, 2016: Markets opened higher on Wednesday following mixed trading in Asia. The dollar weakened and the release of…

Chris Lange | Mar 23, 2016 at 9:05 AM EDT

How Ionis Pharma Beat a Biotech Giant

Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.

Chris Lange | Mar 15, 2016 at 9:25 AM EDT

Jefferies Top Drug Stocks for the Rest of 2016

For the most part, Jefferies maintained its list of top companies in the health care sector, but it also made…

Chris Lange | Mar 10, 2016 at 8:40 AM EST

Major Pharma Short Interest Takes a Small Step Back

The February 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Feb 25, 2016 at 8:10 AM EST

Short Sellers Increase Bets in Major Pharma

The February 12 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | Feb 10, 2016 at 9:15 AM EST

Short Sellers Increase Bets in Major Pharma

The January 29 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Jon C. Ogg | Feb 9, 2016 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce, Tesla, Yelp and More

The top analyst upgrades, downgrades and initiations seen on Tuesday include Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce,com,…

Lee Jackson | Feb 8, 2016 at 8:25 AM EST

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

If you ever want to look for value in a sector in the stock market, then when you see Congress…

Chris Lange | Feb 7, 2016 at 10:15 AM EST

How Analysts View Pfizer and Merck After Earnings

After Pfizer and Merck released their most recent earnings reports last week, analysts weighed in on both of these pharmaceutical…

Chris Lange | Feb 3, 2016 at 8:45 AM EST

Merck Trips Up Over Mixed Earnings

Merck reported mixed fourth-quarter financial results before the markets opened Wednesday.

Chris Lange | Jan 31, 2016 at 10:10 AM EST

Top 3 Dow Earnings for the Coming Week

24/7 Wall St. has put together a preview of the three Dow Jones Industrial Average companies that are reporting their…

Jon C. Ogg | Jan 30, 2016 at 10:50 AM EST

5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet

Some of the Dow stocks that are down in 2016 haven't even reported earnings. This is the market bracing for…

Chris Lange | Jan 28, 2016 at 8:40 AM EST

Short Sellers Become More Selective on Major Pharma

The January 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

1 … 37 38 39 40 41 … 73

Merck : MRK

All Merck Articles

The 4 Stocks That Buoyed the DJIA on Thursday

Short Sellers Become More Selective in Major Pharma

The 4 Stocks That Dominated the Dow on Wednesday

How Ionis Pharma Beat a Biotech Giant

Jefferies Top Drug Stocks for the Rest of 2016

Major Pharma Short Interest Takes a Small Step Back

Short Sellers Increase Bets in Major Pharma

Short Sellers Increase Bets in Major Pharma

Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce, Tesla, Yelp and More

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

How Analysts View Pfizer and Merck After Earnings

Merck Trips Up Over Mixed Earnings

Top 3 Dow Earnings for the Coming Week

5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet

Short Sellers Become More Selective on Major Pharma

Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

YMAX’s 1.33% Fee Is Just the Start: How a Fund-of-Funds Structure Is Quietly Stacking Costs on Top of Costs

How a Couple With $1 Million in Retirement Can Build a Tax-Efficient $2,392 Monthly Income Stream Using 2 Vanguard ETFs

Earned Over $145,000 Last Year? Your 401(k) Catch-Up Money Is Now Forced Into a Roth and Here’s Who Wins

Earned Over $145,000 Last Year? Your 401(k) Catch-Up Money Is Now Forced Into a Roth and Here's Who Wins

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back

YMAX’s 1.33% Fee Is Just the Start: How a Fund-of-Funds Structure Is Quietly Stacking Costs on Top of Costs

How a Couple With $1 Million in Retirement Can Build a Tax-Efficient $2,392 Monthly Income Stream Using 2 Vanguard ETFs

Merck : MRK

All Merck Articles

The 4 Stocks That Buoyed the DJIA on Thursday

Short Sellers Become More Selective in Major Pharma

The 4 Stocks That Dominated the Dow on Wednesday

How Ionis Pharma Beat a Biotech Giant

Jefferies Top Drug Stocks for the Rest of 2016

Major Pharma Short Interest Takes a Small Step Back

Short Sellers Increase Bets in Major Pharma

Short Sellers Increase Bets in Major Pharma

Top Analyst Upgrades and Downgrades: Apple, Freeport-McMoRan, Kinross Gold, Pfizer, Plains All American, Salesforce, Tesla, Yelp and More

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

How Analysts View Pfizer and Merck After Earnings

Merck Trips Up Over Mixed Earnings

Top 3 Dow Earnings for the Coming Week

5 Dow Stocks Getting Slammed in 2016 Have Not Even Reported Earnings Yet

Short Sellers Become More Selective on Major Pharma

Live: Will Aehr Test Systems Crush Tonight’s Q4 Earnings After the Market Closes?

YMAX’s 1.33% Fee Is Just the Start: How a Fund-of-Funds Structure Is Quietly Stacking Costs on Top of Costs

How a Couple With $1 Million in Retirement Can Build a Tax-Efficient $2,392 Monthly Income Stream Using 2 Vanguard ETFs

Earned Over $145,000 Last Year? Your 401(k) Catch-Up Money Is Now Forced Into a Roth and Here’s Who Wins

Featured Reads

Earned Over $145,000 Last Year? Your 401(k) Catch-Up Money Is Now Forced Into a Roth and Here's Who Wins

She Claimed Social Security at 62 and Regretted It Within the Year. One Form Let Her Take It All Back